Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
A funding to expand operations and provide better patient care
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
This new capability represents a significant shift from a microscope-based standard of care to the use of digital whole slide images
Digital success is contingent on the way a company organizes itself around technology
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Rocuronium Bromide Injection is a neuromuscular blocking agent
Subscribe To Our Newsletter & Stay Updated
